Repare Therapeutics Inc. announced that Steve Forte, Executive Vice President and Chief Financial Officer, has been appointed as President and Chief Executive Officer, effective April 11, 2025. Mr. Forte will also join the Board of Directors and will continue to serve as the company’s Chief Financial Officer.
Lloyd M. Segal has resigned from his roles as President, Chief Executive Officer, and member of the Board of Directors, effective April 11, 2025, to pursue other opportunities. Mr. Forte brings over 20 years of finance and biotech leadership experience to his new role, having been integral to Repare’s strategy and financings since 2019.
The company also promoted Sandra Alves, Vice President and Corporate Controller, to Chief Accounting Officer. The leadership transition follows Repare's recent re-alignment of resources and re-prioritization of its clinical portfolio, with a continued focus on advancing its three ongoing Phase 1 clinical trials.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.